ABIOMED INC COM (ABMD) : Nichols Asset Management reduced its stake in ABIOMED INC COM by 0.82% during the most recent quarter end. The investment management company now holds a total of 139,854 shares of ABIOMED INC COM which is valued at $14,241,333 after selling 1,151 shares in ABIOMED INC COM , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.ABIOMED INC COM makes up approximately 3.07% of Nichols Asset Management’s portfolio.
ABIOMED INC COM opened for trading at $101.73 and hit $102.41 on the upside on Wednesday, eventually ending the session at $102.05, with a gain of 0.02% or 0.02 points. The heightened volatility saw the trading volume jump to 2,63,317 shares. Company has a market cap of $4,331 M.
Other Hedge Funds, Including , Strs Ohio sold out all of its stake in ABMD during the most recent quarter. The investment firm sold 92,270 shares of ABMD which is valued $9,395,854.New York State Teachers Retirement System reduced its stake in ABMD by selling 5,753 shares or 6.53% in the most recent quarter. The Hedge Fund company now holds 82,300 shares of ABMD which is valued at $8,380,609. ABIOMED INC COM makes up approx 0.02% of New York State Teachers Retirement System’s portfolio.Gemmer Asset Management boosted its stake in ABMD in the latest quarter, The investment management firm added 6 additional shares and now holds a total of 79 shares of ABIOMED INC COM which is valued at $7,759.Falcon Point Capital boosted its stake in ABMD in the latest quarter, The investment management firm added 23,189 additional shares and now holds a total of 92,459 shares of ABIOMED INC COM which is valued at $9,081,323. ABIOMED INC COM makes up approx 1.60% of Falcon Point Capital’s portfolio.Capstone Asset Management Co reduced its stake in ABMD by selling 560 shares or 4.01% in the most recent quarter. The Hedge Fund company now holds 13,400 shares of ABMD which is valued at $1,316,148. ABIOMED INC COM makes up approx 0.04% of Capstone Asset Management Co’s portfolio.
On the company’s financial health, ABIOMED INC COM reported $0.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Feb 4, 2016. Analyst had a consensus of $0.16. The company had revenue of $85.80 million for the quarter, compared to analysts expectations of $85.81 million. The company’s revenue was up 38.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 EPS.
Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.